X0306 4 2015-07-21 0 0001339469 CHIASMA, INC CHMA 0001358309 MPM BioVentures IV QP LP C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001134657 EVNIN LUKE C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001356950 Scopa James Paul C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001180429 KAILIAN VAUGHN M C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001358313 MPM Asset Management Investors BV4 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001423213 MPM Bio IV NVS Strategic Fund LP C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001412336 MPM BioVentures IV GmbH & Co. Beteiligungs KG C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001358311 MPM BioVentures IV GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001358312 MPM BioVentures IV LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2015-07-21 4 C 0 10426 A 10426 I See Footnote Common Stock 2015-07-21 4 C 0 2488171 A 2498597 I See Footnote Common Stock 2015-07-21 4 C 0 1759381 A 4257978 I See Footnote Common Stock 2015-07-21 4 C 0 1423566 A 5681544 I See Footnote Series B-1' Preferred Stock 2015-07-21 4 C 0 95225 D Common Stock 10426 0 I See Footnote Series C' Preferred Stock 2015-07-21 4 C 0 22721988 D Common Stock 2488171 0 I See Footnote Series D' Preferred Stock 2015-07-21 4 C 0 16066669 D Common Stock 1759381 0 I See Footnote Series E Preferred Stock 2015-07-21 4 C 0 13000000 D Common Stock 1423566 0 I See Footnote The shares, on a common stock equivalent basis, were converted as follows: 9,773 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 376 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 277 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC ("BV GP LLC") and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa and Todd Foley are the members of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares of Series B-1' Preferred Stock, Series C' Preferred Stock, Series D' Preferred Stock and Series E Preferred Stock converted into 0.109505 of a share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. The shares are held as follows: 9,773 by BV IV QP, 376 by BV IV KG and 277 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares, on a common stock equivalent basis, were converted as follows: 1,479,910 by BV IV QP, 57,016 by BV IV KG, 42,083 by AM BV4 and 909,162 by MPM Bio IV NVS Strategic Fund, L.P. ("BV IV SF"). BV GP LLC and BV LLC are the direct and indirect general partners of BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares are held as follows: 1,489,683 by BV IV QP, 57,392 by BV IV KG, 42,360 by AM BV4 and 909,162 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares, on a common stock equivalent basis, were converted as follows: 1,539,486 by BV IV QP, 59,313 by BV IV KG, 43,776 by AM BV4 and 116,806 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares are held as follows: 3,029,169 by BV IV QP, 116,705 by BV IV KG, 86,136 by AM BV4 and 1,025,968 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares, on a common stock equivalent basis, were converted as follows: 939,089 by BV IV QP, 36,179 by BV IV KG, 26,704 by AM BV4 and 421,594 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares are held as follows: 3,968,258 by BV IV QP, 152,884 by BV IV KG, 112,840 by AM BV4 and 1,447,562 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. By Luke Evnin, member of MPM BioVenture IV LLC, the managing member of MPM BioVentures IV GP LLC, the general partner of MPM BioVentures IV-QP, L.P. /s/ Luke Evnin 2015-07-21 /s/ Luke Evnin 2015-07-21 /s/ James Paul Scopa 2015-07-21 /s/ Vaughn M. Kailian 2015-07-21 By Luke Evnin, member of MPM BioVenture IV LLC, the manager of MPM Asset Management Investors BV4 LLC /s/ Luke Evnin 2015-07-21 By Luke Evnin, member of MPM BioVenture IV LLC, the managing member of MPM BioVentures IV GP LLC, the general partner of MPM Bio IV NVS Strategic Fund, L.P. /s/ Luke Evnin 2015-07-21 By Luke Evnin, member of MPM BioVenture IV LLC, the managing member of MPM BioVentures IV GP LLC, the managing limited partner of MPM BioVentures IV GmbH & Co. Beteiligungs KG /s/ Luke Evnin 2015-07-21 By Luke Evnin, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC /s/ Luke Evnin 2015-07-21 By Luke Evnin, member of MPM BioVenture IV LLC /s/ Luke Evnin 2015-07-21